Obesity GLP-1 Coverage and Weight Management Vendor Considerations
Posted on June 25, 2024
2024 Trends in Drug Benefit Design Report Issue Brief
Obesity is one of the largest public health concerns in the United States, as it affects over 40% of the adult population and is associated with various health conditions and poor health outcomes. For many people, lifestyle modification alone does not produce sufficient weight loss, and the entrance of GLP-1 drugs for obesity offers promise. At the same time, these drugs come with list prices over $10k per year, and perceptions remain mixed on whether obesity is a chronic disease for which pharmaceuticals should be covered or a lifestyle condition for which pharmaceuticals should not be covered. Regardless of whether an organization chooses to cover GLP-1s for obesity, given the high prevalence of overweight and obesity and the tremendous attention on obesity, organizations may consider working with a weight management point solution vendor for help in this area.
In PSG’s recent Trends in Drug Benefit Design survey, we asked health plans and employers about their perspectives and strategies related to GLP-1s. Download the issue brief to learn how organizations are viewing GLP-1 coverage for obesity, what to look for in a weight management point solution vendor, and more.
